Durvalumab

Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Durvalumab and local guidelines before prescribing.

Immune checkpoint inhibitor

Mechanism

PD-L1 inhibitor.

Uses

Lung cancer, biliary tract cancer, hepatocellular carcinoma.

Dosing

No dose is given in the chapters. See the BNF.

Side effects

Immune-related pneumonitis, hepatitis, colitis, endocrinopathies.

Interactions

Steroids reduce effect.

Contraindications and cautions

Autoimmune disease caution

Monitoring

TFT, LFT, cortisol

Pregnancy and breastfeeding

Avoid

Renal and hepatic impairment

No adjustment

Overdose and reversal

Supportive

Special advice

Early identification and steroid treatment of immune toxicity.

More from the textbook: uses, cautions and other points
Where it is discussed in the book